2 weeks Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Lags Revenue Estimates Zacks

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -3.45% and 75.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?